Abstract
Apart from increased production of immunoglobulin E antibodies and disturbed T-cell regulation, altered patterns of releasability of vasoactive mediators have been described in patients with atopic eczema. The best studied substance is histamine; elevated concentrations of histamine have been found in vivo in the skin and in the plasma of patients with atopic eczema. Similar findings have been described recently for leukotriene B4. At present no single mediator substance can be defined as characteristic trigger of atopic eczema. Future studies in the field of mediator research may lead to new therapeutic approaches for the treatment of atopic eczema.
| Translated title of the contribution | Inflammatory mediators in atopic eczema |
|---|---|
| Original language | German |
| Pages (from-to) | 60-62 |
| Number of pages | 3 |
| Journal | Allergologie |
| Volume | 11 |
| Issue number | 2 |
| State | Published - 1988 |
| Externally published | Yes |